Tofacitinib, n = 1535 | 815 (53.1) | 1.04 (0.94–1.19) | NA | NA |
bDMARD, n = 9849 | 5546 (56.3) | 0.83 (0.78–0.86) | 0.90 (0.83–0.97) | 0.90 (0.83–0.97) |
Adalimumab, n = 2343 | 1396 (59.6) | 0.71 (0.67–0.77) | 0.81 (0.75–0.89) | 0.81 (0.74–0.89) |
Certolizumab pegol, n = 746 | 466 (62.5) | 0.64 (0.53–0.71) | 0.72 (0.65–0.81) | 0.72 (0.64–0.81) |
Etanercept, n = 1562 | 916 (58.6) | 0.71 (0.65–0.82) | 0.82 (0.75–0.90) | 0.81 (0.73–0.89) |
Golimumab, n = 837 | 430 (51.4) | 1.00 (0.87–1.17) | 1.04 (0.93–1.17) | 1.04 (0.92–1.18) |
Infliximab, n = 695 | 357 (51.4) | 1.13 (0.97–1.49) | 1.10 (0.97–1.25) | 1.10 (0.97–1.25) |
Abatacept, n = 2132 | 1154 (54.1) | 0.90 (0.84–0.99) | 0.96 (0.88–1.05) | 0.96 (0.87–1.05) |
Tocilizumab, n = 1534 | 827 (53.9) | 0.89 (0.80–0.98) | 0.96 (0.87–1.06) | 0.96 (0.87–1.06) |